Merit Medical Systems has obtained 510(k) approval from the US Food and Drug Administration (FDA) to expand indication for QuadraSphere Microspheres to include the embolization of hepatoma.
Malignant hepatoma or otherwise called hepatocellular carcinoma (HCC) is claimed to be sixth most common cancer and the third leading cause of cancer deaths across the globe.
The company has designed QuadraSphere Microspheres to provide controlled and targeted embolization to treat HCC. It will help in stopping the blood flow to the tumours.
Merit Medical Systems chairman and CEO Fred Lampropoulos said: "The FDA’s clearance of QuadraSphere for the embolization of hepatoma provides another treatment option for patients and physicians in their battle against primary liver cancer.
"This clearance also represents a milestone in our continual efforts to improve patients’ lives through the development of innovative technologies that produce better patient outcomes."
Merit Medical develops and markets disposable medical devices used in interventional and diagnostic procedures, specifically in cardiology, radiology and endoscopy.